Zahid Cheema, MD
Neurology · Oklahoma City, OKNPI 1417924507
Payments from drug & device makers
Across 760 payments — averaging $38.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$11K
- Argenx US, Inc.$4K
- AbbVie$2K
- UCB, Inc.$2K
- SK Life Science, Inc.$803
- Teva Pharmaceuticals USA, Inc.$658
- plus $9K from 51 others
What the payments were for
- Consulting fees$3,16317%
- Speaking & faculty fees$470%
- Travel & lodging$100%
- Food & beverage$14,63381%
- Education$2862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,538
- INFINITY$296
- BRIUMVI$150
- VYVGART HYTRULO$125
How this compares
$29,019 in reported general payments places this provider in the 80th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 126 | $1,330,928 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 72 | $821,463 |
| Radicava OrsEdaravone | 36 | $512,780 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 59 | $510,258 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $277,414 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $217,199 |
| Plegridy PenPeginterferon Beta-1a | 16 | $130,275 |
| VumerityDiroximel Fumarate | 13 | $111,514 |
| NourianzIstradefylline | 12 | $23,304 |
| XcopriCenobamate | 20 | $23,090 |
| Nurtec OdtRimegepant Sulfate | 18 | $18,273 |
| BriviactBrivaracetam | 13 | $17,941 |
| GlatopaGlatiramer Acetate | 12 | $16,963 |
| Lacosamide | 49 | $10,008 |
| Mycophenolate Mofetil | 68 | $9,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $398 | $839,73790 claims |
| Grifols USA, LLCGamunex-C | $165 | $510,25859 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $222 | $277,41422 claims |
| CSL BehringPrivigen | $408 | $217,19912 claims |
| BiogenVumerity | $475 | $111,51413 claims |
| UCB, Inc.Briviact, Neupro | $1,613 | $26,75724 claims |
| Kyowa Kirin, Inc.Nourianz | $193 | $23,30412 claims |
| SK Life Science, Inc.Xcopri | $803 | $23,09020 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $306 | $13,975124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Gabriel PardoOklahoma City$10.3M
- Cherian KarunapuzhaOklahoma City$4.1M
- James BattisteOklahoma City$1.1M
- Mariana VargaOklahoma City$670K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Evgeny SidorovOklahoma City$212K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$168K
- Erika Santos HortaOklahoma City$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.